Dana-Farber Cancer Institute and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center recognized for exceptional outcomes in donor stem cell transplants
6 Key Takeaways
-
1
Dana-Farber received a +1 score from the CIBMTR for adult and pediatric stem cell programs.
-
2
This is the sixth year for the adult program and the second for pediatric.
-
3
Only 8 centers in the US outperformed in stem cell transplants.
-
4
Dana-Farber is the sole center exceeding survival benchmarks in the largest transplant centers.
-
5
The CIBMTR report assesses outcomes among 176 U.S. programs and adjusts for patient complexity.
-
6
Allogeneic transplants treat serious conditions like leukemias and lymphomas.
Dana-Farber Brigham Cancer Center has achieved remarkable ratings in stem cell transplantation, receiving a +1 score from the Center for International Blood & Marrow Transplant Research for both its adult and pediatric programs. This distinction recognizes their ability to surpass the expected one-year survival rate for allogeneic stem cell transplants in the U.S. Notably, this is the sixth consecutive year for the adult program and the first for the pediatric program, marking a significant achievement in patient care and multidisciplinary collaboration.
Listen Tab content
